About News News Subscribe Economics Education Health Policy Facet Area of Focus - News Ian H. Solomon Craig Volden Brian N. Williams Christine Mahoney Benjamin Castleman Kirsten Gelsdorf Gerald Warburg Gabrielle Adams Philip Potter Daphna Bassok Jay Shimshack Lucy Bassett John Holbein Andrew S. Pennock David Leblang Allan Stam Raymond C. Scheppach Sophie Trawalter Timothy L. Davis Bala Mulloth Benjamin Converse Sebastian Tello Trillo Eileen Chou Jeanine Braithwaite Jennifer Lawless Jill Rockwell Todd S. Sechser Alexander Bick James H. Wyckoff Paul S. Martin Peter Johannessen Steve Hiss Daniel W. Player Gerard Robinson Laura Toscano Michael D. Williams Noah Myung William Shobe Brooke Lehmann Harry Harding James R. Detert Jazmin Brown-Iannuzzi Jeff Chidester Kyle S. H. Dobson Larry Terry Margaret Foster Riley Molly Lipscomb Abigail Scholer Adam Leive Allison Atteberry Andrew Simon Brad Carson Derek Wu Frederick P. Hitz Galen Fountain Gerald Higginbotham Isaac Mbiti Michele Claibourn Sally Hudson Tim Layton Xiao Wang Adam Roux Amanda Crombie Andy Ortiz Ashley Jardina Brendan J. Boler Brooke Ray Charles J. Rush Charles J. Rush Diane Biesecker George Foresman Jieun Pai Justin H. Kirkland Kimberly Jenkins Robinson Melissa Thomas-Hunt Pam Cipriano Paul Becker Tim Layton (-) Sarah Turner (-) Christopher J. Ruhm Facet People - News EdPolicyWorks: Center for Education Policy and Workforce Competitiveness Facet UVA Partner - News Research and Commentary Accolades Faculty In Action Facet News Type - News May 17, 2021 How to target opioid funding to states that need it most Health Policy Economics According to new research from Batten’s Christopher J. Ruhm, the federal government’s opioid grant funding structure favors the least populous states, which are not always the states with greatest need. In an op-ed for The Hill, Ruhm suggests several ways to improve the targeting of federal grants that aim to assist states with opioid problems. Read in The Hill May 03, 2021 Federal Opioid Grant Funding Favors Least Populous States, Not Those With the Greatest Need Economics Health Policy In a new paper published in the journal Health Affairs, Batten’s Christopher J. Ruhm and co-author Bradley A. Katcher find that the federal government’s opioid grant funding structure favors the least populous states, which are not always the states with greatest need. Learn more Apr 26, 2020 Health and Wealth: UVA Economists Examine COVID-19’s Impact Economics Health Policy As the economy experiences a steep recession, a panel of UVA economists including Batten's Sarah Turner and David Bradford examined the implications for the nation’s material and physical health. READ IN UVA TODAY Apr 09, 2020 How Might the COVID-19 Recession Affect Your Health? An Economist Explains. Economics Health Policy Recessions may be good for overall physical health, but this one could be different. Batten professor Chris Ruhm presented an online talk Wednesday offering an economist’s view of the overall health effects of the COVID-19 recession. His talk was the school’s third installment of its expert chat series about COVID-19. Learn more Nov 21, 2019 New Research: Non-Opioid Drug Death Rates Are Also on the Rise Economics The number of Americans dying from drug overdoses has risen rapidly in the last decade, with opioids viewed as the primary culprit. However, recent research suggests that opioids are not the only drug involved. According to Batten professor of economics, Christopher J. Ruhm, half of the overdose deaths have involved polydrug use and deaths involving nonopioid drugs are rising almost as fast as those involving opioids. READ IN UVA TODAY Pagination Previous page ‹ Previous Page 1 Current page 2 Stay Up To Date with the Latest Batten News and Events Subscribe
May 17, 2021 How to target opioid funding to states that need it most Health Policy Economics According to new research from Batten’s Christopher J. Ruhm, the federal government’s opioid grant funding structure favors the least populous states, which are not always the states with greatest need. In an op-ed for The Hill, Ruhm suggests several ways to improve the targeting of federal grants that aim to assist states with opioid problems. Read in The Hill
May 03, 2021 Federal Opioid Grant Funding Favors Least Populous States, Not Those With the Greatest Need Economics Health Policy In a new paper published in the journal Health Affairs, Batten’s Christopher J. Ruhm and co-author Bradley A. Katcher find that the federal government’s opioid grant funding structure favors the least populous states, which are not always the states with greatest need. Learn more
Apr 26, 2020 Health and Wealth: UVA Economists Examine COVID-19’s Impact Economics Health Policy As the economy experiences a steep recession, a panel of UVA economists including Batten's Sarah Turner and David Bradford examined the implications for the nation’s material and physical health. READ IN UVA TODAY
Apr 09, 2020 How Might the COVID-19 Recession Affect Your Health? An Economist Explains. Economics Health Policy Recessions may be good for overall physical health, but this one could be different. Batten professor Chris Ruhm presented an online talk Wednesday offering an economist’s view of the overall health effects of the COVID-19 recession. His talk was the school’s third installment of its expert chat series about COVID-19. Learn more
Nov 21, 2019 New Research: Non-Opioid Drug Death Rates Are Also on the Rise Economics The number of Americans dying from drug overdoses has risen rapidly in the last decade, with opioids viewed as the primary culprit. However, recent research suggests that opioids are not the only drug involved. According to Batten professor of economics, Christopher J. Ruhm, half of the overdose deaths have involved polydrug use and deaths involving nonopioid drugs are rising almost as fast as those involving opioids. READ IN UVA TODAY